Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 322 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Follow-Up Questions
Who is the CEO of Mirum Pharmaceuticals Inc?
Mr. Christopher Peetz is the Chief Executive Officer of Mirum Pharmaceuticals Inc, joining the firm since 2018.
What is the price performance of MIRM stock?
The current price of MIRM is $71.01, it has increased 0.06% in the last trading day.
What are the primary business themes or industries for Mirum Pharmaceuticals Inc?
Mirum Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Mirum Pharmaceuticals Inc market cap?
Mirum Pharmaceuticals Inc's current market cap is $3.5B
Is Mirum Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Mirum Pharmaceuticals Inc, including 7 strong buy, 9 buy, 1 hold, 0 sell, and 7 strong sell
